YUROXAN
Dead / Cancelled — Cancelled — Section 8 (as of 25 May 2018)
What this means for you
This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 77942356
- Registration number
- 4040189
- Mark type
- Stylized text
- Filed
- 23 Feb 2010
- Published for opposition
- 02 Aug 2011
- Registered
- 18 Oct 2011
- Attorney of record
- Adrienne L. White
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and veterinary preparations for humans and animals, namely, medicines, vaccines, and serums for diagnostics, testing, prevention, treatment, and therapeutics, in particular medicines for treating cardiovascular illnesses, in particular hyperlipidaemia, coronary heart diseases and cardiac insufficiency; medicines for the treatment of immunological diseases, in particular autoimmune diseases in particular rheumatic disorders, polychondritis, Bechterew's disease, fibromyalgia and lupus erythematodes, rheumatoid arthritis, polyarthritis, Crohn's disease, and multiple sclerosis; medicines for treating skin diseases, in particular acne, actinic keratosis, alopecia, atopic dermatitis, Bowen's disease, cutaneous atopy, cutaneous T-cell lymphoma, Darrier's disease, Dartroud diathesis, dermatitis, eczema, genital herpes, genital warts, herpes, hyperkeratosis, hyperpigmentation, hyperplasia of the epidermis, hypopigmentation, ichthyosis, increased proliferation of skin cells, keloids, lentigo, lichen planus, melasma, molluscum contagiosum, mycosis fungoides, neoplasias, neurodermitis, pigmentation disorders, porokeratosis of Mibelli, psoriasis, removal of tattoos, rosacea, seborrhea, seborrheic keratosis, shingles, skin diseases related to inflammatory processes of skin cells, skin ulcers, vitiligo, warts, xerosis; medicines for treating tumourous diseases, in particular Astrocytomas, basal cell carcinomas, biliary cancers, bladder cancers, bone cancers, brain cancers, breast cancers, carcinomas, cervical cancers, cervical intraepithelial neoplasias, colorectal cancers, endocrine system cancers, ependymomas, epidermoid carcinomas, fibrosarcomas, gastric cancers, gastrointestinal cancers, glioblastomas, gynecologic cancers, head and neck cancers, hemangiomas, hepatomas, Hodgkin's lymphomas, Leukemia, liver cancers, lung cancers, lymphomas, medulloblastomas, meningiomas, mesothelaiomas, metastases, myelomas, neoplasias, neurectodermal cancers, neuroblastomas, neurofibromas, neurofibrosarcomas, neuronal cancers, non-Hodgkin's lymphomas, oligodendrogliomas, ovarian carcinoma, pancreatic cancers, pediatric cancers, penile cancer, pituitary adenomas, pleural cancers, renal cancer, sarcomas, Schwannomas, skin cancers, sqamous cell carcinomas, testicular cancers, thyroid cancers, thyroid tumors, urinary tract cancers, carcinoma of the prostate, melanoma, Kaposi's sarcoma, hepatocellular carcinoma; ALL OF THE ABOVE CONSISTING OF low-molecular active substances, liposomes, aptamers, nucleic acids, peptides, proteins, protein conjugates, antibodies, T-cell proteins, enzymes and enzyme preparations, hormones, hormone analogues, attenuated viruses, virus-type particles and plant extracts
Owner
- MediGene AG, Planegg/Martinsried, DE
- MediGene AG, Planegg/Martinsried, DE
- MediGene AG, Planegg/Martinsried, DE
Prior registrations
Prosecution history
- 25 May 2018 — CANCELLED SEC. 8 (6-YR)
- 18 Oct 2016 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 18 Oct 2011 — REGISTERED-PRINCIPAL REGISTER
- 02 Aug 2011 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Aug 2011 — PUBLISHED FOR OPPOSITION
- 28 Jun 2011 — LAW OFFICE PUBLICATION REVIEW COMPLETED
- 24 Jun 2011 — ASSIGNED TO LIE
- 22 Jun 2011 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Jun 2011 — EXAMINER'S AMENDMENT ENTERED
- 22 Jun 2011 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 22 Jun 2011 — EXAMINERS AMENDMENT E-MAILED
- 22 Jun 2011 — EXAMINERS AMENDMENT -WRITTEN
- 03 Jan 2011 — NOTIFICATION OF PRIORITY ACTION E-MAILED
- 03 Jan 2011 — PRIORITY ACTION E-MAILED
- 03 Jan 2011 — PRIORITY ACTION WRITTEN